These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. RenaGel efficacy in severe secondary hyperparathyroidism. Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746 [TBL] [Abstract][Full Text] [Related]
6. [Hydroxyproline in the dialysate as a parameter of secondary hyperparathyroidism. Effects of phosphate reduction and alkalization]. Schiessl JH; Schweigart U; Bottermann P; Kopp KF Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1310-3. PubMed ID: 25525 [No Abstract] [Full Text] [Related]
7. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335 [TBL] [Abstract][Full Text] [Related]
8. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)]. Novikov AI Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540 [No Abstract] [Full Text] [Related]
9. [Front line of management of hyperphosphatemia in hemodialysis patients]. Yumita S Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041 [TBL] [Abstract][Full Text] [Related]
10. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523 [TBL] [Abstract][Full Text] [Related]
12. [Disorders of calcium and phosphorus metabolism in renal failure and nephrotic syndrome]. Kubota M; Ohno T Nihon Rinsho; 1982; 40(12):2673-9. PubMed ID: 6761460 [No Abstract] [Full Text] [Related]
13. [Radioimmunologic determination of circulating parathyroid hormone in patients with primary and secondary hyperparathyroidism]. Lo Giudice C; Cascone C; Manente P; Gasparoni P; De Luca M; Rota G; Conte N Minerva Med; 1982 Dec; 73(48):3425-8. PubMed ID: 7177469 [TBL] [Abstract][Full Text] [Related]
16. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. Salusky IB; Foley J; Nelson P; Goodman WG N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306 [TBL] [Abstract][Full Text] [Related]
17. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications? Wang AY; Woo J; Sea MM; Law MC; Lui SF; Li PK Am J Kidney Dis; 2004 Apr; 43(4):712-20. PubMed ID: 15042549 [TBL] [Abstract][Full Text] [Related]
18. Is there increasing evidence to change the management of renal bone disease? Harum P Nephrol News Issues; 1999 Apr; 13(4):55-6. PubMed ID: 10418451 [No Abstract] [Full Text] [Related]
19. [Characteristics of phosphorus metabolism in patients with acute disorders of cerebral circulation]. ChepkiUi LP; Pas'ko SA; Volosheniuk TG; Sofienko GI Vrach Delo; 1989 Dec; (12):27-9. PubMed ID: 2629271 [TBL] [Abstract][Full Text] [Related]
20. Control of hyperphosphatemia among patients with ESRD. Coladonato JA J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]